Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making

  • Geriatric Oncology
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

To prevent breast cancer-related recurrence and death, adjuvant therapy, including chemotherapy, is given. The decision to deliver chemotherapy requires careful weighing of the risk of toxicity versus the estimated benefit. The risk and benefit are based on information from clinical trials, statistical models, and past clinical experience . Compared to younger patients, it is perceived that older patients have cancers that are lower risk, gain less benefit from chemotherapy, and are at higher risk of toxicity. There is now strong evidence that healthy older women tolerate treatment and stand to gain the same benefits from treatment as do younger women. Numeric age alone, therefore, does not justify withholding adjuvant chemotherapy. New tools to aid in the decision are needed. Fortunately, the expected great increase in the size of the geriatric population spawned the field of geriatric oncology and the development of brief, practical versions of the Comprehensive Geriatric Assessment (CGA) for use in busy oncology clinics are in sight. It is time for us to incorporate elements of the CGA into practice, to systematically identify older patients at substantial risk of toxicity. For frail older women with breast cancer, no therapy or less toxic therapies can be considered, some of which are suggested herein. In addition, as always in oncology, physicians and patients should look for and participate in clinical trials that will define how to treat cancer, especially in older patients, in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance

  1. Yancik R. Cancer burden in the aged—an epidemiologic and demographic overview. Cancer. 1997;80(7):1273.

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  3. Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer. 1989;63:976.

    Article  PubMed  CAS  Google Scholar 

  4. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21(19):3580.

    Article  PubMed  Google Scholar 

  5. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138(2):90–7.

    PubMed  Google Scholar 

  6. Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer. 2004;90(8):1486–91.

    Article  PubMed  CAS  Google Scholar 

  7. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687.

    Article  Google Scholar 

  8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Article  PubMed  CAS  Google Scholar 

  10. Kimmick G, Hughes K, Muss HB. Breast cancer in older women. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast, vol fourth. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 1059–72.

    Google Scholar 

  11. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Jama. 2006;295(14):1658–67.

    Article  PubMed  CAS  Google Scholar 

  12. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials, Early Breast Cancer Trialists’ Collaborative Group. Lancet. 2008;371(9606):29–40.

    Article  PubMed  CAS  Google Scholar 

  13. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81.

    Article  PubMed  CAS  Google Scholar 

  14. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–6.

    Article  PubMed  Google Scholar 

  15. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24(18):2757–64.

    Article  PubMed  Google Scholar 

  16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    Article  PubMed  CAS  Google Scholar 

  17. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

    Article  PubMed  CAS  Google Scholar 

  18. Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F, Glas AM. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomarkers Insights. 2010;5:129–38.

    Google Scholar 

  19. Wittner BS, Sgroi DC, Ryan PD, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008;14(10):2988–93.

    Article  PubMed  CAS  Google Scholar 

  20. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25(24):3699–704.

    Article  PubMed  CAS  Google Scholar 

  21. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Groups Trial VII. J Clin Oncol. 2000;18:1412.

    PubMed  CAS  Google Scholar 

  22. Kimmick GG, Fleming R, Muss HB, Balducci L. Cancer chemotherapy in older adults—a tolerability perspective. Drugs Aging. 1997;10(1):34–49.

    Article  PubMed  CAS  Google Scholar 

  23. Wildiers H. Challenges in treating older cancer patients: breast cancer. Ann Oncol. 2008;Suppl 7:vii99–103.

    Article  Google Scholar 

  24. Lichtman SM, Wildiers H, Chatelut E, et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832–43.

    Article  PubMed  CAS  Google Scholar 

  25. Launay-Vacher V, Spano JP, Janus N, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70(2):124–33.

    Article  PubMed  Google Scholar 

  26. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am. 2000;14(1):45–61. viii.

    Article  PubMed  CAS  Google Scholar 

  27. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12(12):1416–24.

    Article  PubMed  CAS  Google Scholar 

  28. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25(25):3871–6.

    Article  PubMed  Google Scholar 

  29. Renella R, Verkooijen HM, Fioretta G, et al. Increased risk of acute myeloid leukaemia after treatment for breast cancer. Breast. 2006;15(5):614–9.

    Article  PubMed  CAS  Google Scholar 

  30. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–15.

    Article  PubMed  CAS  Google Scholar 

  31. Hurria A, Lachs MS, Cohen HJ, Muss HB, Kornblith AB. Geriatric assessment for oncologists: rationale and future directions. Crit Rev Oncol Hematol. 2006;59(3):211–7.

    Article  PubMed  Google Scholar 

  32. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol. 2000;18(8):1709–17.

    PubMed  CAS  Google Scholar 

  33. Ferrucci L, Guralnik JM, Cavazzini C, et al. The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol. 2003;46(2):127–37.

    Article  PubMed  Google Scholar 

  34. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31.

    Article  PubMed  Google Scholar 

  35. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–52.

    Article  PubMed  Google Scholar 

  36. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–91.

    Article  PubMed  Google Scholar 

  37. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007;43(15):2161–9.

    Article  PubMed  Google Scholar 

  38. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005.

    Article  PubMed  Google Scholar 

  39. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401. J Clin Oncol. 2011

  40. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104.

    PubMed  CAS  Google Scholar 

  41. Satariano WA. Aging, comorbidity, and breast cancer survival: an epidemiologic view. Adv Exp Med Biol. 1993;330:1.

    PubMed  CAS  Google Scholar 

  42. Bergman L, Dekker G, van Leeuwen FE, Huisman SJ, Van Dam FS, van Dongen JA. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer. 1991;67:2227.

    Article  PubMed  CAS  Google Scholar 

  43. Hurria A, Hurria A, Zuckerman E, et al. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006;54(7):1119–24.

    Article  PubMed  Google Scholar 

  44. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96(17):1311.

    Article  PubMed  Google Scholar 

  45. Ferrucci L, Guralnik JM, Studenski S, Fried LP, Cutler Jr GB, Walston JD. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc. 2004;52(4):625–34.

    Article  PubMed  Google Scholar 

  46. Rockwood K, Howlett SE, MacKnight C, et al. Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging. J Gerontol A Biol Sci Med Sci. 2004;59(12):1310–7.

    Article  PubMed  Google Scholar 

  47. Mor V, Wilcox V, Rakowski W, Hiris J. Functional transitions among the elderly: patterns, predictors, and related hospital use. Am J Public Health. 1994;84(8):1274–80.

    Article  PubMed  CAS  Google Scholar 

  48. Dittus K, Muss HB. Management of the frail elderly with breast cancer. Oncology (Williston Park). 2007;21(14):1727–34. discussion 1737, 1740.

    Google Scholar 

  49. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J Clin Oncol. 2002;20(2):494.

    Article  PubMed  Google Scholar 

  50. Monfardini S, Ferrucci L, Fratino L, del Lungo I, Serraino D, Zagonel V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 1996;77(2):395–401.

    Article  PubMed  CAS  Google Scholar 

  51. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59(3):255–63.

    Article  PubMed  Google Scholar 

  52. Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–7.

    Article  PubMed  Google Scholar 

  53. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–9.

    Article  PubMed  CAS  Google Scholar 

  54. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci. 2009;64(10):1049–57.

    Article  PubMed  Google Scholar 

  55. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114(3):180–7.

    Article  PubMed  Google Scholar 

  56. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54(6):991–1001.

    Article  PubMed  Google Scholar 

  57. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.

    Article  PubMed  CAS  Google Scholar 

  58. Singh MA. Exercise to prevent and treat functional disability. Clin Geriatr Med. 2002;18(3):431–62. vi–vii.

    Article  PubMed  Google Scholar 

  59. Leveille SG, Guralnik JM, Ferrucci L, Langlois JA. Aging successfully until death in old age: opportunities for increasing active life expectancy. Am J Epidemiol. 1999;149(7):654–64.

    PubMed  CAS  Google Scholar 

  60. Landi F, Cesari M, Onder G, Lattanzio F, Gravina EM, Bernabei R. Physical activity and mortality in frail, community-living elderly patients. J Gerontol A Biol Sci Med Sci. 2004;59(8):833–7.

    Article  PubMed  Google Scholar 

  61. Extermann M, Meyer J, McGinnis M, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol. 2004;49(1):69.

    Article  PubMed  Google Scholar 

  62. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study. J Clin Oncol. 2010;28(15s):abstr 9001.

    Google Scholar 

  63. Extermann M, Boler I, Reich R, et al. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: design and validation. J Clin Oncol. 2010;28(15s):abstr 9000.

    Google Scholar 

  64. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061.

    Article  PubMed  CAS  Google Scholar 

  65. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6.

    Article  PubMed  CAS  Google Scholar 

  66. Kimmick G, Kornblith A, Mandelblatt J, et al. A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001. J Clin Oncol. 2004;22(14):739S.

    Google Scholar 

  67. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. 29th Annual SABCS. 2006(Abstract 52)

  68. Jones SE, Collea RP, Oratz R, et al. Cardiac safety results of a phase ii trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab (Her TC) in HER2+ early stage breast cancer patients. Cancer Res. 2009;69(24 Supplement):5082.

    Article  Google Scholar 

  69. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597–605.

    Article  PubMed  Google Scholar 

  70. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–7.

    Article  PubMed  CAS  Google Scholar 

  71. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–83

    Article  PubMed  CAS  Google Scholar 

  72. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483.

    PubMed  CAS  Google Scholar 

  73. De Maio E, Gravina A, Pacilio C, et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer. 2005;5:30.

    Article  PubMed  Google Scholar 

  74. Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007;19(4):299–307.

    Article  PubMed  Google Scholar 

  75. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–65.

    Article  PubMed  CAS  Google Scholar 

  76. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21(8):1431.

    Article  PubMed  CAS  Google Scholar 

  77. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    Article  PubMed  CAS  Google Scholar 

  78. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park). 2009;23(2):133–42.

    Google Scholar 

  79. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol. 2004;22(23):4622–30.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Multidisciplinary Breast Program, Duke University Medical Center, DUMC Box 3204, 10 Bryan-Searle Drive, Seeley G. Mudd Bldg, Durham, NC, 27710, USA

    Gretchen Kimmick MD, MS

Authors
  1. Gretchen Kimmick MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gretchen Kimmick MD, MS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimmick, G. Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making. Curr. Treat. Options in Oncol. 12, 286–301 (2011). https://doi.org/10.1007/s11864-011-0159-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0159-z

Keywords

Search

Navigation